Surrozen 2025 Q3 Earnings Record High Net Loss Surges 4896%

, , driven by non-cash valuation hits and soaring R&D costs. , while the stock underperformed in post-earnings strategies. The company remains focused on ophthalmology pipeline advancements despite financial strain.

Revenue

, driven entirely by research services from a related party, which accounted for the entire revenue figure. , reflecting reduced collaboration revenue and a strategic pivot to ophthalmology.

Earnings/Net Income

, , . Non-cash losses, , were primary contributors. This performance underscores the company’s heavy reliance on R&D spending and lack of revenue diversification. The earnings outcome represents a significant deterioration in financial health.

Post-Earnings Price Action Review

The strategy of buying Surrozen shares on quarterly earnings dates and holding for 30 days has historically underperformed, . Post-Q3, . While short-term volatility persists, the broader trend highlights challenges in aligning stock performance with earnings outcomes.

CEO Commentary

CEO emphasized progress in ophthalmology pipeline candidates SZN-8141 and SZN-8143, with an IND submission for SZN-8141 planned in 2026. The hiring of CFO and strengthened leadership aim to accelerate clinical development and strategic partnerships, including the Boehringer Ingelheim collaboration.

Guidance

Surrozen expects to submit an IND for SZN-8141 in 2026 and advance SZN-8143 and SZN-413 toward clinical trials. . The company remains focused on retinal disease therapies, leveraging Wnt biology expertise and scientific conferences to build pipeline visibility.

Additional News

Surrozen appointed Andrew Maleki as CFO, effective November 12, , strengthening financial leadership amid its ophthalmology focus. The company also confirmed plans to submit an IND for SZN-8141 in 2026, a key milestone for its pipeline. Additionally, Surrozen’s partnership with Boehringer Ingelheim for SZN-413 remains a strategic cornerstone, with potential milestone payments and royalties. These developments highlight the company’s long-term growth strategy despite near-term financial challenges.